BRCA-P: An International Randomised Phase III Study Evaluating The RANK Ligand Inhibitor Denosumab For The Prevention Of Breast Cancer In BRCA1 Mutation Carriers
Funder
National Health and Medical Research Council
Funding Amount
$2,589,049.00
Summary
Women with a faulty BRCA1 gene are at high lifetime risk for breast cancer. Identifying a safe and effective prevention therapy is therefore a ‘holy grail’. We have discovered that denosumab, used to treat osteoporosis or breast cancer spread to bone, could be ‘repurposed’ as a prevention drug. BRCA-P is an international randomised controlled study that will determine if denosumab prevents breast cancer. Associated translational research will facilitate swift transfer to the clinic.
Functional Characterization And Therapeutic Targeting Of The Novel Long Noncoding RNA RP1-40E16.9
Funder
National Health and Medical Research Council
Funding Amount
$673,447.00
Summary
Cancer is the most common cause of death from diseases in children. Neuroblastoma is the most common solid tumour in early childhood. In this project, we will define the role of a novel long non-protein-coding RNA in promoting neuroblastoma initiation and progression. We will also define the anti-cancer efficacy of a novel therapy targeting the long non-protein-coding RNA.
Targeting JMJD6 Gene Gain For The Therapy Of Neuroblastoma
Funder
National Health and Medical Research Council
Funding Amount
$381,012.00
Summary
Cancer is the most common cause of death from disease in children. Neuroblastoma is the most prevalent solid tumour in early childhood. In this project, we will define the key role of JMJD6 gene gain in neuroblastoma cell proliferation, survival and tumourigenesis. We will also identify a novel therapeutic strategy for the treatment of neuroblastoma.